These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 32541170)
1. [Analgesic Effects of Mirogabalin for Cancer Pain]. Nakanishi K; Ota C; Yomiya K Gan To Kagaku Ryoho; 2020 Jun; 47(6):927-931. PubMed ID: 32541170 [TBL] [Abstract][Full Text] [Related]
2. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study. Tetsunaga T; Tetsunaga T; Nishida K; Misawa H; Takigawa T; Yamane K; Tsuji H; Takei Y; Ozaki T J Orthop Surg Res; 2020 May; 15(1):191. PubMed ID: 32456647 [TBL] [Abstract][Full Text] [Related]
3. Occurrence of somnolence and respiratory depression induced by pregabalin and mirogabalin use and the influence of opioid treatment using the Japanese adverse drug event report database. Kato H; Koseki T; Kondo M Pharmazie; 2024 Aug; 79(7):169-172. PubMed ID: 39152553 [No Abstract] [Full Text] [Related]
4. Mirogabalin besylate in the treatment of neuropathic pain. Burgess J; Javed S; Frank B; Malik RA; Alam U Drugs Today (Barc); 2020 Feb; 56(2):135-149. PubMed ID: 32163529 [TBL] [Abstract][Full Text] [Related]
5. Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the Domon Y; Arakawa N; Inoue T; Matsuda F; Takahashi M; Yamamura N; Kai K; Kitano Y J Pharmacol Exp Ther; 2018 Jun; 365(3):573-582. PubMed ID: 29563324 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S J Diabetes Investig; 2020 May; 11(3):693-698. PubMed ID: 31722446 [TBL] [Abstract][Full Text] [Related]
7. Analgesic effects of mirogabalin, a novel ligand for α Saeki K; Yasuda SI; Kato M; Kano M; Domon Y; Arakawa N; Kitano Y Naunyn Schmiedebergs Arch Pharmacol; 2019 Jun; 392(6):723-728. PubMed ID: 30770951 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige Kitano Y; Kai K; Yamamura N; Yoshiba S; Kuroha M Nihon Yakurigaku Zasshi; 2019; 154(6):352-361. PubMed ID: 31787689 [TBL] [Abstract][Full Text] [Related]
9. A large-scale database study for the prescription status of a new voltage-gated Ca Ushida T; Yokoyama M; Shiosakai K; Saito K; Ibe S; Okuizumi K Expert Opin Pharmacother; 2022 Feb; 23(2):273-283. PubMed ID: 34928189 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Vinik A; Rosenstock J; Sharma U; Feins K; Hsu C; Merante D; Diabetes Care; 2014 Dec; 37(12):3253-61. PubMed ID: 25231896 [TBL] [Abstract][Full Text] [Related]
11. The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids. Tang H; Lu J; Duan Y; Li D Mediators Inflamm; 2023; 2023():4893436. PubMed ID: 37152369 [TBL] [Abstract][Full Text] [Related]
12. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. Hutmacher MM; Frame B; Miller R; Truitt K; Merante D J Clin Pharmacol; 2016 Jan; 56(1):67-77. PubMed ID: 26073181 [TBL] [Abstract][Full Text] [Related]
13. Anxiolytic effects of the novel α Murasawa H; Kobayashi H; Saeki K; Kitano Y Psychopharmacology (Berl); 2020 Jan; 237(1):189-197. PubMed ID: 31515584 [TBL] [Abstract][Full Text] [Related]
14. Mirogabalin: First Global Approval. Deeks ED Drugs; 2019 Mar; 79(4):463-468. PubMed ID: 30778848 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery: the multicenter, randomized, open-label ADMIT-NeP study. Miyazaki T; Matsumoto K; Sato T; Sano I; Furukawa K; Shimoyama K; Kamohara R; Suzuki M; Kondou M; Ikeda N; Tabata S; Shiosakai K; Nagayasu T; BMC Cancer; 2024 Jan; 24(1):80. PubMed ID: 38225552 [TBL] [Abstract][Full Text] [Related]
16. Analgesic effects of the novel α₂δ ligand mirogabalin in a rat model of spinal cord injury. Domon Y; Kitano Y; Makino M Pharmazie; 2018 Nov; 73(11):659-661. PubMed ID: 30396385 [TBL] [Abstract][Full Text] [Related]
17. Mirogabalin as a Therapeutic Option for Neuropathic Pain Emerging Post-endodontic Treatment: A Two-Case Report. Shimizu K; Yasukawa T; Ohara K; Noma N; Hayashi M; Takeichi O J Endod; 2024 Sep; 50(9):1351-1356. PubMed ID: 38901645 [TBL] [Abstract][Full Text] [Related]
18. Predictors of the usefulness of mirogabalin for neuropathic pain: a single-institution retrospective study. Kanbayashi Y; Amaya F; Ikoma K; Ueno H; Tabuchi Y; Ishikawa T; Takayama K; Taguchi T Pharmazie; 2020 Nov; 75(11):602-605. PubMed ID: 33239138 [TBL] [Abstract][Full Text] [Related]
19. Analgesic characteristics of a newly developed α Komatsu S; Nakamura S; Nonaka T; Yamada T; Yamamoto T Mol Pain; 2021; 17():17448069211052167. PubMed ID: 34823399 [TBL] [Abstract][Full Text] [Related]